The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lutetium-177 Vipivotide Tetraxetan Drug Master File in Japan (Lutetium-177 Vipivotide Tetraxetan JDMF) empowers Lutetium-177 Vipivotide Tetraxetan API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lutetium-177 Vipivotide Tetraxetan JDMF during the approval evaluation for pharmaceutical products. At the time of Lutetium-177 Vipivotide Tetraxetan JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lutetium-177 Vipivotide Tetraxetan suppliers with JDMF on PharmaCompass.